Arthron Sales
This is what PRR and Southern Cross Equity Reported in Oct 2005:
Arthron (85%): Represents a next generation rheumatoid arthritis drug based on the FCƒ×RIIa receptor, a good upstream target for rheumatoid arthritis and a billion dollar a year market for ¡¥TNF non-responders¡¦. The Arthron technology is ready for licensing and is attracting interest from overseas Pharmas. We value Prima¡¦s interest in Arthron at $20.1m-$54m.
This is what PRR management achieved and was reported in the Lodge Report:
¡§About a year later, on 06 October 2005, Prima announced the sale of all Arthron assets to Trillium Therapeutics Inc. (Toronto, Canada). Prima received an up-front payment of US$500,000 and 7% equity stake in Trillium (currently valued by Prima at $A3.2m). Trillium is continuing all of Arthron¡¦s R&D collaborations and, as research milestones are met, Prima¡¦s share in Trillium could increase to 13%¡¨
So SCE valued Arthron at $20 to 50 million and Eugene and Marcus managed to do a deal a year later valued at $3.7 million now read on¡K¡K..
And now here¡¦s how PRR represented the deal at their 2006 AGM:
¡§That the Company approve the issue to Mr. Eugene Kopp of one hundred and seventy-eight
thousand one hundred and twenty five (178,125) ordinary shares in the capital of the
Company deemed fully paid at an issue price of eight and a half cents ($0.085) per share.¡¨
Subject to shareholders approval, Mr. Eugene Kopp will be issued a total of one hundred and seventy eight thousand one hundred and twenty-five (178,125) ordinary shares in the capital of the Company, fully paid at a deemed issue price of eight and one half cents ($0.085) each as a bonus associated with the Trillium Therapeutics transaction.
¡§That the Company approve the issue to Mr. Marcus Clark of seven hundred and twenty-four
thousand three hundred and seventy-five (724,375) ordinary shares in the capital of the
Company deemed fully paid at an issue price of eight and a half cents ($0.085) per share.¡¨
Subject to shareholders approval, Mr. Marcus Clark will be issued a total of seven hundred and
twenty-four thousand three hundred and seventy-five (724,375) ordinary shares in the capital of the Company, fully paid at a deemed issue price of eight and one half cents ($0.085) each as a bonus associated with the Trillium Therapeutics transaction.
These guys paid themselves a bonus for a serious reduction in shareholder value ¡V what a hide !
- Forums
- ASX - By Stock
- IMM
- lets talk about arthron
lets talk about arthron
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 581 | 37.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 17500 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 811 | 0.395 |
2 | 2615 | 0.380 |
3 | 16918 | 0.370 |
2 | 36000 | 0.365 |
4 | 139181 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 17500 | 3 |
0.370 | 16253 | 3 |
0.375 | 112892 | 2 |
0.380 | 49650 | 2 |
0.385 | 113595 | 6 |
Last trade - 09.25am 26/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
Day chart unavailable
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online